Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Kresladi Coverage Prior Auth | OpenPaye…
    Ask Trek AI about this page
    ModifiedQualChoicePolicy CP.PHAR.599

    Marnetegragene Autotemcel (Kresladi)

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.599 alerts

    Get alerted when Policy CP.PHAR.599 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Kresladi, an autologous gene therapy for pediatric patients with severe leukocyte adhesion deficiency type 1 (LAD-I). It applies to QualChoice commercial, HIM/ICHRA, and Medicaid members and requires PDAC utilization management review.

    Policy Summary
    PayerQualChoice
    PolicyMarnetegragene Autotemcel (Kresladi)
    Policy CodePolicy CP.PHAR.599
    Change TypeModified
    Effective DateApr 22, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot scheduled
    Key ActionSubmit documentation supporting all approval criteria for PDAC Utilization Management Review.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was updated after marnetegragene autotemcel became FDA approved, with criteria revised to align with FDA labeling.

    The policy clarified that the ITGB2 gene mutation must be biallelic and added an age requirement of less than 18 years based on prescribing information.

    Additional severe-disease options were added, including genetic testing, delayed umbilical cord separation, omphalitis, and LAD-I-related clinical events.

    The generic name was added and the former designation RP-L201 was updated to Kresladi.

    <18 yearsAge requirement
    1/lifetimeTreatment frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2.8×10^6 CD34+/kg
    Single-infusion dose
    3 monthsApproval duration
    FDA approvedRegulatory status

    Coverage Criteria

    Initial Therapy Criteria — LAD-I

    Covered for LAD-I when all of the following are met:

    Initial LAD-I criteria

    • Confirmed LAD-I by flow cytometry

      • Pathway A: CD18 expression is below 2% of polymorphonuclear neutrophils (PMNs).CD18 < 2% of PMNs
      • Pathway B

        • CD11a or CD11b expression is below 2% of PMNs.CD11a or CD11b < 2% of PMNs
        • Genetic testing confirms a biallelic pathogenic or likely pathogenic ITGB2 gene mutation.Biallelic pathogenic or likely pathogenic ITGB2 variant
        • Clinical history is consistent with LAD-I or there is a known family history.

          See Appendix D for examples of clinical history.

    • Specialist prescribing: The request is prescribed by or in consultation with a transplant specialist and one of the following: hematologist, oncologist, immunologist, or infectious disease specialist.
    • Age: Member is younger than 18 years of age.< 18 years
    • Severe disease

      • Member has a family history of LAD-I.
      • Member has had at least one prior significant bacterial or fungal infection.>= 1 infection

        See Appendix D for examples.

      • Genetic testing confirms a biallelic pathogenic or likely pathogenic ITGB2 gene mutation.
      • Member had severe, medically significant, or life-threatening omphalitis or delayed umbilical-cord separation at birth.Cord separation after 21 days of life
      • Member has had at least two severe or medically significant LAD-I-related clinical events within any consecutive 18-24-month period.>= 2 events in 18-24 months
    • No matched sibling donor: Member has no available HLA-matched sibling donor.
    • Transplant eligibility: A transplant specialist attests that the member is clinically stable and eligible to undergo myeloablative conditioning and HSCT.
    • Dose: The requested dose is a single infusion containing at least 2.8 x 10^6 CD34+ cells/kg.>= 2.8 x 10^6 CD34+ cells/kg

    Other Diagnoses or Indications

    For other diagnoses or indications, one of the following pathways must apply:

    Other diagnosis or indication

    • Recent label change: If the drug underwent a label change within the last 6 months that is not reflected in this policy, refer to the applicable no-coverage or non-formulary policy based on formulary or PDL status and line of business.Within the last 6 months

      Commercial: CP.CPA.190; HIM/ICHRA: HIM.PA.33 or HIM.PA.103; Medicaid: CP.PMN.255 or CP.PMN.16.

    • Unlisted use: If the requested diagnosis, age, or dosing regimen is not specifically listed under the non-authorized indications section and the recent-label-change pathway does not apply, refer to the applicable off-label use policy.

      Commercial: CP.CPA.09; HIM/ICHRA: HIM.PA.154; Medicaid: CP.PMN.53.

    Continued Therapy

    Continued therapy follows the applicable pathway below:

    Continuation therapy

    • LAD-I: No reauthorization is permitted because Kresladi is dosed one time only.1 dose per lifetime

      Approval duration is not applicable.

    • Other indications: For other diagnoses or indications, apply the recent-label-change or unlisted-use referral pathways described for initial therapy.

    Non-FDA-approved indications not addressed by this policy are not authorized unless sufficient documentation of efficacy and safety supports coverage under the applicable off-label use policy or evidence of coverage documents.

    Coding and Clinical Thresholds

    HCPCS CodesHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals
    CD18 expression on neutrophils
    CD18 expression below threshold< 2% of polymorphonuclear neutrophils (PMNs)
    CD18 expression at or above threshold≥ 2% of PMNs when all qualifying additional findings are present
    Qualifying additional findingsCD11a or CD11b expression < 2% of PMNs; biallelic pathogenic or likely pathogenic ITGB2 mutation; and clinical history consistent with LAD-I or known family history
    CD11a or CD11b expression
    Required expression level< 2% of PMNs
    MarkersCD11a or CD11b

    Provider Actions and Review Requirements

    Prior Authorization

    PDAC Utilization Management Review Required

    All requests under this policy require Precision Drug Action Committee (PDAC) Utilization Management Review. Submit the request for PDAC review according to the process in CC.PHAR.21.

    Documentation Required

    Submit Clinical Documentation

    Provider must submit documentation supporting that the member meets all approval criteria, including office chart notes, laboratory results, and other relevant clinical information.

    • Include clinical records supporting the diagnosis, disease severity, treatment history, specialist evaluations, donor assessment, and clinical stability for conditioning and HSCT.
    Documentation Required

    Therapy Background

    Kresladi (marnetegragene autotemcel) is an autologous hematopoietic stem cell-based gene therapy carrying a functional copy of the ITGB2 gene. It is indicated for pediatric patients with severe leukocyte adhesion deficiency type 1 (LAD-I) caused by biallelic ITGB2 variants who do not have an available HLA-matched sibling donor for allogeneic hematopoietic stem cell transplantation.

    Definitions

    Clinical history consistent with LAD-I
    Umbilical-cord findingDelayed detachment after birth of at least 3 weeks, often progressing to inflammation of the umbilical-cord stump and surrounding tissues (omphalitis)
    Inflammatory manifestationsInflammation of the skin and mucous membranes, including the lining of the nose, mouth, and gums
    Other manifestationsLack of pus formation at infection sites and delayed wound healing due to impaired immune response
    Significant bacterial or fungal infection
    Characteristic patternSystemic, persistent, recurrent, severe, or progressing to large areas of the body
    Soft-tissue examplesGingivitis and periodontitis involving the gums and tissues around the teeth

    Initial Therapy Criteria

    Initial Kresladi Therapy — LAD-I

    Initial Kresladi therapy is covered for LAD-I when all of the following criteria are met:

    LAD-I initial therapy

    • Confirmed LAD-I by flow cytometry

      • Pathway A: CD18 expression is below 2% of PMNs.CD18 < 2% of PMNs
      • Pathway B

        • CD11a or CD11b expression is below 2% of PMNs.CD11a or CD11b < 2% of PMNs

    Continuation Criteria

    LAD-I Continuation Therapy

    For LAD-I continuation therapy:

    No reauthorization: Kresladi is a one-time infusion and may not be reauthorized for LAD-I.1 dose per lifetime

    Approval duration is not applicable.

    Other-Indication Continuation Therapy

    For other diagnoses or indications, use the applicable recent-label-change or off-label policy pathway:

    Other-indication continuation pathway

    • Recent label change: If a label change within the last 6 months is not reflected in this policy, refer to the applicable no-coverage or non-formulary policy based on formulary or PDL status and line of business.Within the last 6 months

    Quantity and Dose Limits

    Marnetegragene autotemcel (Kresladi)
    Lifetime quantity limit1 dose per lifetime
    Treatment frequencyOne-time treatment
    ProductMarnetegragene autotemcel (Kresladi)
    Marnetegragene autotemcel (Kresladi)
    Minimum dose2.8 x 10^6 CD34+ cells/kg
    AdministrationSingle intravenous infusion
    Course limitOne dose per lifetime
    Policy Summary
    PayerQualChoice
    PolicyMarnetegragene Autotemcel (Kresladi)
    Policy CodePolicy CP.PHAR.599
    Change TypeModified
    Effective DateApr 22, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot scheduled
    Key ActionSubmit documentation supporting all approval criteria for PDAC Utilization Management Review.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Actions and Review RequirementsTherapy BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity and Dose Limits

    Examples include pyoderma gangrenosum or periodontitis.

    Test method
    Flow cytometry
    Delayed umbilical-cord separation
    Qualifying thresholdSeparation after 21 days of life
    Clinical contextDelayed umbilical-cord separation at birth
    Severe-disease criterionMay qualify when severe, medically significant, or life-threatening
    Severe LAD-I-related clinical events
    Minimum eventsAt least 2 severe or medically significant LAD-I-related clinical events
    Time periodWithin any consecutive 18–24-month period
    ExamplesInflammatory events such as pyoderma gangrenosum or periodontitis
    Kresladi dose
    Minimum dose2.8 x 10^6 CD34+ cells/kg
    AdministrationSingle intravenous infusion
    FrequencyOnce

    LAD-I Eligibility Evidence Required

    Document LAD-I eligibility with the required diagnostic and clinical evidence. Diagnosis must be confirmed by flow cytometry, with genetic testing and clinical or family-history support when applicable.

    • Flow cytometry must show CD18 expression on < 2% of neutrophils (PMNs); or CD18 expression on ≥ 2% of PMNs together with CD11a or CD11b expression on < 2% of PMNs.
    • When CD18 is ≥ 2%, provide genetic testing confirming a biallelic pathogenic or likely pathogenic ITGB2 mutation and a clinical history consistent with LAD-I or a known family history.
    • Provide documentation that treatment is prescribed by or in consultation with a transplant specialist and a hematologist, oncologist, immunologist, or infectious disease specialist.
    • Provide evidence of severe disease, such as a qualifying infection or LAD-I-related clinical event, severe omphalitis or delayed umbilical cord separation, family history, or qualifying ITGB2 genetic findings.
    • Document that the member is under 18 years of age, has no available HLA-matched sibling donor, and is clinically stable and eligible for myeloablative conditioning and HSCT, with transplant specialist attestation.
    • The requested dose must be a single infusion containing at least 2.8 × 106 CD34+ cells/kg.
    Denial Risk

    Non-FDA-Approved Indications Not Authorized

    Kresladi is not authorized for non-FDA-approved indications that are not addressed by this policy, unless the required efficacy and safety documentation supports coverage under the applicable off-label use policy.

    • For commercial members, refer to CP.CPA.09; for health insurance marketplace/ICHRA members, refer to HIM.PA.154; for Medicaid members, refer to CP.PMN.53 or the applicable evidence of coverage documents.
    Denial Risk

    Failure to Meet LAD-I Criteria May Result in Denial

    Requests are at risk for denial when any LAD-I approval requirement is not documented or is not met.

    • LAD-I diagnosis is not confirmed by the required flow-cytometry findings and, when applicable, biallelic pathogenic or likely pathogenic ITGB2 mutation testing and supporting clinical or family history.
    • Member is age 18 years or older, does not have severe disease as defined by the policy, or the required clinical history or events are not documented.
    • Member has an available HLA-matched sibling donor.
    • Required prescribing or consultation by a transplant specialist and a hematologist, oncologist, immunologist, or infectious disease specialist is absent.
    • Transplant specialist does not attest that the member is clinically stable and eligible for myeloablative conditioning and HSCT.
    • Requested dose is not a one-time infusion containing at least 2.8 × 106 CD34+ cells/kg, or other approval criteria are unmet.
    Denial Risk

    No Reauthorization for Repeat Treatment

    Reauthorization is not permitted. Kresladi is indicated as a one-time treatment and is not approved for repeat dosing.

    • Approval duration is 3 months for the one-time infusion; continued-therapy approval duration is not applicable.
    Other examplesOtitis media, pneumonia, peritonitis, and deep abscesses
    HLA
    AbbreviationHLA
    DefinitionHuman leukocyte antigen
    Policy-related donor referenceHLA-matched sibling donor
    HSCT
    AbbreviationHSCT
    DefinitionHematopoietic stem cell transplantation
    Policy-related eligibility referenceEligibility to undergo myeloablative conditioning and HSCT
    LAD-I
    AbbreviationLAD-I
    DefinitionLeukocyte adhesion deficiency type 1
    Associated clinical findingsDelayed umbilical-cord detachment, omphalitis, impaired pus formation, and delayed wound healing
    Genetic testing confirms a biallelic pathogenic or likely pathogenic ITGB2 gene mutation.
  1. Clinical history is consistent with LAD-I or there is a known family history.
  2. The request is prescribed by or in consultation with a transplant specialist and a hematologist, oncologist, immunologist, or infectious disease specialist.
  3. Member is younger than 18 years of age.< 18 years
  4. Severe disease

    • Family history of LAD-I.
    • At least one prior significant bacterial or fungal infection.>= 1 infection
    • Biallelic pathogenic or likely pathogenic ITGB2 gene mutation confirmed by genetic testing.
    • Severe, medically significant, or life-threatening omphalitis or delayed umbilical-cord separation at birth.Cord separation after 21 days of life
    • At least two severe or medically significant LAD-I-related clinical events within any consecutive 18-24-month period.>= 2 events in 18-24 months
  5. Member has no available HLA-matched sibling donor.
  6. A transplant specialist attests that the member is clinically stable and eligible to undergo myeloablative conditioning and HSCT.
  7. The dose is a single infusion containing at least 2.8 x 10^6 CD34+ cells/kg.>= 2.8 x 10^6 CD34+ cells/kg

    Approval duration is 3 months for one infusion per lifetime.

  8. Other-Indication Initial Therapy

    Other diagnoses or indications must follow the applicable line-of-business pathway:

    Other-indication initial pathway

    • Recent label change: If a label change within the last 6 months is not reflected in this policy, refer to the applicable no-coverage or non-formulary policy based on formulary or PDL status and line of business.Within the last 6 months

      Commercial: CP.CPA.190; HIM/ICHRA: HIM.PA.33 or HIM.PA.103; Medicaid: CP.PMN.255 or CP.PMN.16.

    • Unlisted use: If the requested diagnosis, age, or dosing regimen is not specifically listed under the non-authorized indications section and the recent-label-change pathway does not apply, refer to the applicable off-label use policy.

      Commercial: CP.CPA.09; HIM/ICHRA: HIM.PA.154; Medicaid: CP.PMN.53.

    Commercial: CP.CPA.190; HIM/ICHRA: HIM.PA.33 or HIM.PA.103; Medicaid: CP.PMN.255 or CP.PMN.16.

  9. Unlisted use: If the requested use is not specifically listed under the non-authorized indications section and the recent-label-change pathway does not apply, refer to the applicable off-label use policy.

    Commercial: CP.CPA.09; HIM/ICHRA: HIM.PA.154; Medicaid: CP.PMN.53.